Results 41 to 50 of about 15,820 (232)

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension

Vascular Health and Risk Management, 2008
M Kathryn Steiner1, Ioana R Preston21Pulmonary Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; 2Pulmonary Critical Care and Sleep Division, Department of Medicine, Tufts Medical Center, Boston, MA, USAAbstract:
M Kathryn Steiner, Ioana R Preston
doaj  

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Bladder Endothelin-1 Receptor Binding of Bosentan and Ambrisentan

Journal of Pharmacological Sciences, 2014
.: The present study aimed to characterize bladder endothelin-1 (ET-1) receptor binding of clinically used ET-1 receptor antagonists by using [125I]ET-1.
Ayaka Osano, Yoshinari Yokoyama, Hideki Hayashi, Kunihiko Itoh, Takashi Okura, Yoshiharu Deguchi, Yoshihiko Ito, Shizuo Yamada   +7 more
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Endothelin‐1 and Endothelin Receptor Antagonists in Cardiovascular Remodeling

Proceedings of the Society for Experimental Biology and Medicine, 1999
Endothelins build a peptide family composed of three isoforms, each of them containing 21 amino acids. Endothelin‐1 is the isoform mainly responsible for any cardiovascular action and therefore the sole scope of this review. Endothelin‐1 is the most potent endogenous vasoconstrictor known; in addition it acts as a potent (co)mitogen.
M, Kirchengast, K, Münter
openaire   +2 more sources

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr, Stanislav Keranov, Paulina van Wickern, Holger Nef, Christian Hamm, Pascal Bauer, Christian Troidl, Samuel Sossalla, Sandra Voss, Christoph Liebetrau, Manuel J. Richter, Henning Gall, Werner Seeger, Ardeschir Ghofrani, Athiththan Yogeswaran, Khodr Tello   +15 more
wiley   +1 more source

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension

Drug Design, Development and Therapy, 2009
Kari E Roberts, Ioana R PrestonPulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, Massachusetts, USAAbstract: Endothelin receptor antagonism has emerged as an important therapeutic approach in pulmonary arterial hypertension (PAH).
Kari E Roberts, Ioana R Preston
doaj  

Pharmacotherapy of pulmonary hypertension (according to the 2015 ESC/EAS Guidelines for the diagnosis and treatment of pulmonary hypertension)

Рациональная фармакотерапия в кардиологии, 2016
Indications and efficacy of drugs used for the treatment of pulmonary hypertension are considered. Stages of the treatment of pulmonary arterial hypertension are discussed, including maintenance therapy, specific therapy with calcium channel blockers ...
E. L. Trisvetova, S. V. Gubkin
doaj   +1 more source

A Long-Term Survivor With Alveolar Capillary Dysplasia

JACC: Case Reports, 2020
A patient with alveolar capillary dysplasia has survived more than 56 months with medical therapy. Intrauterine exposure to metformin potentially modified the severity of disease.
Chandler E. Yost, BS, Angelica R. Putnam, MD, Megan K. Dishop, MD, Lynda O. Jorgensen, RN, Paul E. Wirkus, MD, Ronald W. Day, MD   +5 more
doaj   +1 more source